Detecting changes in tumor hypoxia with carbonic anhydrase IX and pimonidazole

Cancer Biology and Therapy

Volumn 6, Issue 1, 2007, Pages 70-75

  Kyung, Hwan Shin ^a,b,c   Diaz Gonzalez, Juan A ^a,c   Russell, James ^a,c   Chen, Qing ^a   Burgman, Paul ^a   Li, Xiao Feng ^a   Ling, C Clifton ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b National Cancer Center   (South Korea)

^c UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Carbogen; Carbonic anhydrase IX; Hydralazine; Pimonidazole; Tumor hypoxia

Indexed keywords

BIOLOGICAL MARKER; CARBOGEN; CARBONATE DEHYDRATASE IX; HOE 33342; HYDRALAZINE; PIMONIDAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME RELEASE; HALF LIFE TIME; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; REOXYGENATION; TISSUE DISTRIBUTION; TISSUE OXYGENATION; TUMOR; TUMOR MODEL; TUMOR XENOGRAFT;

EID: 33847106005     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.1.3550     Document Type: Article

References (40)

1. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955; 9:539-49.
2. Ballinger JR. 99mTc-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J Clin Pharmacol 2001; (Suppl):39S-47S.
3. Chapman JD, Engelhardt EL, Stobbe CC, Schneider RF, Hanks GE. Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays. Radiother Oncol 1998; 46:229-37.
4. Evans SM, Kachur AV, Shiue CY, Hustinx R, Jenkins WT, Shive GG, Karp JS, Alavi A, Lord EM, Dolbier Jr WR, Koch CJ. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 2000; 41:327-36.
5. Hockel M, Knoop C, Schlenger K, Vorndran B, Knapstein PG, Vaupel P. Intratumoral pO2 histography as predictive assay in advanced cancer of the uterine cervix. Adv Exp Med Biol 1994; 345:445-50.
6. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM, Krohn KA. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36:417-28.
7. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997; 38:285-9.
8. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-9.
9. Moulder JE, Rockwell S. Tumor hypoxia: Its impact on cancer therapy. Cancer Metastasis Rev 1987; 5:313-41.
10. Rofstad EK, Sundfor K, Lyng H, Trope CG. Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia induced radiation resistance rather than hypoxia-induced metastasis. Br J Cancer 2000; 83:354-9.
11. Wilson RE, Keng PC, Sutherland RM. Drug resistance in Chinese hamster ovary cells during recovery from severe hypoxia. J Natl Cancer Inst 1989; 81:1235-40.
12. Kim IH, Brown JM. Reoxygenation and rehypoxiation in the SCCVII mouse tumor. Int J Radiat Oncol Biol Phys 1994; 29:493-7.
13. Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation therapy: Their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 1986; 12:681-5.
14. Olive PL. Radiation-induced reoxygenation in the SCCVII murine tumour: Evidence for a decrease in oxygen consumption and an increase in tumour perfusion. Radiother Oncol 1994; 32:37-46.
15. Rofstad EK. Hypoxia and reoxygenation in human melanoma xenografts. Int J Radiat Oncol Biol Phys 1989; 17:81-9.
16. van Putten LM, de Ruiter J, van der Vecht B. Reoxygenation between radiotherapy fractions in an experimental osteosarcoma. Eur J Cancer Clin Oncol 1985; 21:1561-2.
17. Kallman RF. The phenomenon of reoxygenation and its implications for fractionated radiotherapy. Radiology 1972; 105:135-42.
18. Dietz A, Vanselow B, Rudat V, Conradt C, Weidauer H, Kallinowski F, Dollner R. Prognostic impact of reoxygenation in advanced cancer of the head and neck during the initial course of chemoradiation or radiotherapy alone. Head Neck 2003; 25:50-8.
19. Hill RP, Fyles W, Milosevic M, Pintilie M, Tsang RW. Is there a relationship between repopulation and hypoxia/reoxygenation? Results from human carcinoma of the cervix. Int J Radiat Biol 2003; 79:487-94.
20. Semenza GL. Hypoxia-inducible factor 1: Oxygen homeostasis and disease pathophysiology. Trends Mol Med 2001; 7:345-50.
21. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med 2002; 8(4 Suppl):S62-7.
22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32.
23. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004; 3:164-7.
24. Rafajova M, Zatovicova M, Kettmann R, Pastorek J, Pastorekova S. Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. Int J Oncol 2004; 24:995-1004.
25. Vordermark D, Kaffer A, Riedl S, Katzer A, Flentje M. Characterization of carbonic anhydrase IX (CA IX) as an endogenous marker of chronic hypoxia in live human tumor cells. Int J Radiat Oncol Biol Phys 2005; 61:1197-207.
26. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, Oosterhof GO, Witjes JA, Koenders EB, Oyen WJ, Buijs WC, Debruyne FM, Corstens FH, Oosterwijk E. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997; 15:1529-37.
27. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1alpha in perinecrotic regions of solid tumors. Cancer Res 2005; 65:7259-66.
28. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol 1996; 271:C1172-80.
29. Olive PL, Durand RE, Raleigh JA, Luo C, Aquino-Parsons C. Comparison between the comet assay and pimonidazole binding for measuring tumour hypoxia. Br J Cancer 2000; 83:1525-31.
30. Ihnatko R, Kubes M, Takacova M, Sedlakova O, Sedlak J, Pastorek J, Kopacek J, Pastorekova S. Extracellular acidosis elevates carbonic anhydrase IX in human glioblastoma cells via transcriptional modulation that does not depend on hypoxia. Int J Oncol 2006; 29:1025-33.
31. Ljungkvist AS, Bussink J, Rijken PF, Raleigh JA, Denekamp J, Van Der Kogel AJ. Changes in tumor hypoxia measured with a double hypoxic marker technique. Int J Radiat Oncol Biol Phys 2000; 48:1529-38.
32. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure - An obstacle in cancer therapy. Nat Rev Cancer 2004; 4:806-13.
33. Chaplin DJ. Hydralazine-induced tumor hypoxia: A potential target for cancer chemotherapy. J Natl Cancer Inst 1989; 81:618-22.
34. Fenton BM. Influence of hydralazine administration on oxygenation in spontaneous and transplanted tumor models. Int J Radiat Oncol Biol Phys 2001; 49:799-808.
35. Chaplin DJ. The effect of therapy on tumour vascular function. Int J Radiat Biol 1991; 60:311-25.
36. Leith JT, Padfield G, Faulkner L, Michelson S. Hypoxic fractions in xenografted human colon tumors. Cancer Res 1991; 51:5139-43.
37. Sorensen BS, Hao J, Overgaard J, Vorum H, Honore B, Alsner J, Horsman MR. Influence of oxygen concentration and pH on expression of hypoxia induced genes. Radiother Oncol 2005; 76:187-93.
38. Hall E, Giacca A. Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott, Williams and Wilkins, 2006.
39. Turner KJ, Crew JP, Wykoff CC, Watson PH, Poulsom R, Pastorek J, Ratcliffe PJ, Cranston D, Harris AL. The hypoxia-inducible genes VEGF and CA9 are differentially regulated in superficial vs invasive bladder cancer. Br J Cancer 2002; 86:1276-82.
40. Wen B, Urano M, O'Donoghue JA, Ling CC. Measurements of partial oxygen pressure pO2 using the OxyLite system in R3327-AT tumors under isoflurane anesthesia. Radiat Res 2006; 166:512-8.